December 4th 2024
Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Panelists discuss how clinically -diagnosed (or functional) Familial Chylomicronemia Syndrome (FCS), involving a bi-allelic genetic defect, differs in diagnostic approach from classical FCS, emphasizing the challenges of diagnosing without genetic confirmation.
Panelists discuss how genetic mutations, such as mutations in the LPL gene, play a critical role in the pathophysiology of Familial Chylomicronemia Syndrome (FCS) by impairing triglyceride metabolism and increasing the risk of severe hypertriglyceridemia.
PPAR Agonists for Treatment of PBC
December 4th 2024The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.
Comparing the Latest Stool- Based and Blood-Based Colorectal Cancer Screening Tests
December 3rd 2024Vivek Kaul, MD, discusses the sensitivity and accuracy of the stool DNA test, providing relevant data, while also describing the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests.